Oropharyngeal Cancer Treatment Approaches

Introduction to Treatment Options

• The National Comprehensive Cancer Network (NCCN) recommends transoral robotic surgery (TORS) with concurrent neck dissection as an evidence-based option for HPV-positive early stage disease (T1-T2, N0-N1) 2, 6
• The American Society of Clinical Oncology (ASCO) suggests that TORS is FDA-approved for T1-T2 oropharyngeal tumors and allows precise resection while preserving critical structures for speech and swallowing 6

Treatment Approaches for Locally Advanced Resectable Disease

• The NCCN recommends concurrent chemoradiotherapy with cisplatin 100 mg/m² every 3 weeks as the preferred category 1 treatment approach for locally advanced resectable disease (T3-T4a, N0-N1 or any T, N2-N3) 1, 3, 4
• The NCCN suggests three treatment approaches: concurrent systemic therapy/radiotherapy with cisplatin, primary surgery with appropriate adjuvant therapy, and induction chemotherapy followed by radiotherapy or chemoradiotherapy 1, 4

Adjuvant Therapy Indications

• The NCCN recommends postoperative concurrent chemoradiotherapy as category 1 for extracapsular nodal spread and/or positive mucosal margins 1, 3, 4
• The NCCN suggests that concurrent single-agent cisplatin at 100 mg/m² every 3 weeks is the standard regimen 3

HPV Status Considerations

• The NCCN recommends that HPV testing should be performed for all oropharyngeal squamous cell carcinomas, but HPV status should NOT routinely alter treatment selection outside of clinical trials 1, 4, 5
• The NCCN suggests that HPV-positive patients have improved response to treatment and better survival compared to HPV-negative tumors 1, 4, 5

Critical Quality Metrics

• The American Society of Clinical Oncology (ASCO) suggests that treatment should be delivered at centers with established expertise, with multidisciplinary team management, and adherence to treatment package time standards 2
• The ASCO recommends that total treatment time should not exceed 100 days from surgery to completion of radiotherapy, and postoperative radiotherapy must be initiated within 6 weeks of surgery 2